Skip to Content
Merck
  • TRIM21, a New Component of the TRAIL-Induced Endogenous Necrosome Complex.

TRIM21, a New Component of the TRAIL-Induced Endogenous Necrosome Complex.

Frontiers in molecular biosciences (2021-05-04)
Mélanie Simoes Eugénio, Florence Faurez, Ghania H Kara-Ali, Mélanie Lagarrigue, Perrine Uhart, Marion C Bonnet, Isabelle Gallais, Emmanuelle Com, Charles Pineau, Michel Samson, Jacques Le Seyec, Marie-Thérèse Dimanche-Boitrel
ABSTRACT

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a well-known apoptosis inducer and a potential anticancer agent. When caspases and inhibitors of apoptosis proteins (IAPs) are inhibited, TRAIL induces necroptosis. Molecular mechanisms of necroptosis rely on kinase activation, and on the formation of a necrosome complex, bringing together the receptor-interacting protein kinases 1 and 3 (RIPK1, RIPK3), and the mixed lineage kinase domain-like protein (MLKL). In this study, mass spectrometry approach allowed to identify the tripartite motif containing 21 (TRIM21), an E3 ubiquitin-protein ligase as a new partner of the endogenous TRAIL-induced necrosome. Alteration of TRIM21 expression level, obtained by transient transfection of HT29 or HaCat cells with TRIM21-targeted siRNAs or cDNA plasmids coding for TRIM21 demonstrated that TRIM21 is a positive regulator of TRAIL-induced necroptosis. Furthermore, the invalidation of TRIM21 expression in HT29 cells by CRISPR-Cas9 technology also decreased cell sensitivity to TRAIL-induced necroptosis, a shortcoming associated with a reduction in MLKL phosphorylation, the necroptosis executioner. Thus, TRIM21 emerged as a new partner of the TRAIL-induced necrosome that positively regulates the necroptosis process.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
Anti-FADD Antibody, Upstate®, from rabbit